Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lilabilas
- Development stage
- Unknown
- Lead developer
- Ergon Pharmaceuticals
- Administration
- Oral
01
Overview
**E-OPI** is a marketed oral Ayurvedic capsule from Ergon Pharmaceuticals containing **lilabilas 500 mg**, a traditional herbal-mineral formulation referenced by the manufacturer as being sourced from the Bangladesh National Ayurvedic Formulary. It is marketed in Bangladesh for acid-related gastrointestinal conditions, including hyperacidity, gastritis, gastroesophageal reflux disease, gastric ulcer, and duodenal ulcer. Although the manufacturer describes proton-pump inhibition, that pharmacologic mechanism is not substantiated for the Ayurvedic lilabilas formulation and should not be treated as an established mechanism of action. ([ergonbd.info](https://ergonbd.info/eopi.html))
- Brand names
- E-OPI
- Other names
- EOPI
Beyond the preview
Go deeper on lilabilas.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lilabilas.